Of note, the PKC agonist PMA blocked the inhibition of tumor growth upon triple therapy, and PKCα or CRAF inhibitors (RAF-IN-1, PKC-IN-1) combined with encorafenib/cetuximab treatment suppressed resistant PDX tumor growth (Figure 7, G and H and Supplemental Figure 7C). Here, PRKCA is linked to neoplasm.